News | August 26, 2025
Merck presents new data on cardiovascular disease at ESC Congress 2025
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Subscribe To Our Newsletter & Stay Updated
